Business
Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced fourth quarter and full year 2024 financial results and provided a corporate update.
About this update from Talphera, Inc.
[{"type":"text","content":"The U.S. Food and Drug Administration (FDA) agreed to reduce the number of patients in the NEPHRO CRRT study from 166 to 70","length":123,"tagName":"p","attribs":{}},{"type":"text","content":"Talphera expects the registrational NEPHRO CRRT study to be completed by the end of 2025","length":88,"tagName":"p","attribs":{}},{"type":"text","content":"Cash and investments at December 31, 2024 of $8.9 million, together with the private placement financing recently announced of up to $14.8 million, expected to provide capital through target completion of the NEPHRO study in the fourth quarter of 2025","length":256,"tagName":"p","attribs":{}},{"type":"text","content":"Conference call and webcast to be held Monday, March 31, 2025 at 4:30 pm ET","length":75,"tagName":"p","attribs":{}},{"type":"text","content":"SAN MATEO, Calif., March 31, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced fourth quarter and full year 2024 financial results and provided a corporate update.","length":355,"tagName":"p"},{"type":"text","content":""The recent announcements of the FDA's approval to reduce the study size to 70 patients, the private placement financing, and FDA-agreed study protocol changes, provide strong momentum to support the NEPHRO CRRT study execution," stated Vince Angotti, Chief Executive Officer of Talphera. "These developments, coupled with the addition of new sites with higher enrollment potential, two of which have just started screening patients with six more sites expected in the first half of this year, support our belief that we will complete the study by the end of 2025. In addition, clinicians' continued enthusiasm for Niyad's profile reinforces our confidence in its potential to fill a significant unmet need in the CRRT market," continued Angotti.","length":783,"tagName":"p"},{"type":"text","content":"Fourth Quarter 2024 and Recent Highlights","length":41,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In March 2025, the Company announced it received approval from the U.S. Food and Drug Administration (FDA), on its Prior Approval Supplement (PAS) requesting a reduction in the...